![A double-blind placebo-controlled randomized phase II trial assessing the activity and safety of regorafenib in non-adipocytic sarcoma patients previously treated with both chemotherapy and pazopanib - European Journal of Cancer A double-blind placebo-controlled randomized phase II trial assessing the activity and safety of regorafenib in non-adipocytic sarcoma patients previously treated with both chemotherapy and pazopanib - European Journal of Cancer](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/31eb0a0c-6bc7-47ba-ade4-7a9c93dc588f/gr1_lrg.jpg)
A double-blind placebo-controlled randomized phase II trial assessing the activity and safety of regorafenib in non-adipocytic sarcoma patients previously treated with both chemotherapy and pazopanib - European Journal of Cancer
![L'investissement doit repartir pour assurer la poursuite de la hausse des marchés européens" - Boursorama - Carlton Selection L'investissement doit repartir pour assurer la poursuite de la hausse des marchés européens" - Boursorama - Carlton Selection](https://www.carltonselection.fr/wp-content/uploads/2014/06/daniel_gerino_actualites.png)
L'investissement doit repartir pour assurer la poursuite de la hausse des marchés européens" - Boursorama - Carlton Selection
![Sequence of streamlines for the adjoint-based controlled strategy for γ... | Download Scientific Diagram Sequence of streamlines for the adjoint-based controlled strategy for γ... | Download Scientific Diagram](https://www.researchgate.net/profile/Pierre-Yves-Passaggia/publication/322592041/figure/fig3/AS:613977579077633@1523395070588/Sequence-of-streamlines-for-the-adjoint-based-controlled-strategy-for-g-25-10-5-and.png)